In a patient with rheumatoid arthritis presenting with a chronic cough, what workup and management should be performed?

Chronic Cough in Rheumatoid Arthritis: Workup and Management

In a rheumatoid arthritis patient with chronic cough (>8 weeks), immediately obtain a high-resolution CT (HRCT) chest to evaluate for RA-associated interstitial lung disease (ILD) and bronchiectasis, as these are the most common and serious pulmonary manifestations requiring specific management approaches.

Initial Assessment and Red Flags

First, assess for life-threatening causes that require immediate evaluation 1:

• Hemoptysis - demands urgent investigation
• New cough in smoker >45 years or those aged 55-80 with ≥30 pack-year history
• Prominent dyspnea at rest or night
• Systemic symptoms: fever, weight loss, peripheral edema
• Hoarseness or trouble swallowing
• Recurrent pneumonia

Diagnostic Workup Algorithm

1. High-Resolution CT Chest (Primary Diagnostic Tool)

HRCT is essential as it detects both ILD and bronchiectasis, which affect approximately 8.5% and 8.2% of RA patients at diagnosis respectively, with prevalence increasing by 3% and 1.1% per year of RA duration 2. HRCT should be performed in all RA patients with chronic cough or those with RA duration exceeding 5 years 2.

2. Clinical Evaluation for Specific Patterns

• ILD presentation: Progressive dyspnea, dry cough, bibasilar crackles
• Bronchiectasis presentation: Chronic productive cough with sputum, frequent respiratory infections 3
• Document RA disease activity markers (CRP elevation correlates with bronchiectasis risk, increasing prevalence by 3.1% per mg/dL CRP) 2

3. Additional Investigations

• Pulmonary function tests with DLCO
• Sputum cultures if productive cough (rule out infection)
• Consider bronchoscopy if necrotizing tracheobronchitis suspected (rare but reported) 4
• Exclude drug-induced causes (methotrexate pneumonitis, ACE inhibitor cough)

4. Rule Out Common Chronic Cough Causes

Per CHEST guidelines, evaluate for 1:

• Upper airway cough syndrome (rhinosinus conditions)
• Asthma/eosinophilic bronchitis
• Gastroesophageal reflux disease (note: acid suppression alone is no longer recommended)
• Environmental/occupational exposures

Management Based on Diagnosis

If RA-Associated ILD is Confirmed:

For stable RA-ILD, the 2026 Pan American League guidelines conditionally recommend 5:

• Methotrexate (can be continued if already on it)
• Rituximab
• Abatacept (strongest evidence among biologics) 5
• Targeted synthetic DMARDs (JAK inhibitors - though use cautiously given recent safety concerns)

Avoid TNF inhibitors - evidence is mixed and other options have more reliable data 5.

For progressive fibrotic RA-ILD, add antifibrotic therapy 5:

• Pirfenidone or Nintedanib

If Bronchiectasis is Confirmed:

Implement multimodal treatment 3:

Non-pharmacologic interventions:

• Pulmonary rehabilitation program
• Airway clearance techniques education
• Exercise/muscle strengthening program

Pharmacologic management:

• Prophylactic antibiotics if ≥3 exacerbations/year or severe infections requiring hospitalization 3
• Inhaled corticosteroids + long-acting β2-agonists if airway hyperresponsiveness present 3
• Pneumococcal and influenza vaccines (essential to reduce infection risk) 3

DMARD considerations:

• Carefully weigh immunomodulatory drug use - essential for RA control but increase infection risk 3
• Requires joint rheumatology-pulmonology management 3

Critical Pitfalls to Avoid

1. Don't delay HRCT - clinical examination and chest X-ray are insufficient for detecting early ILD or bronchiectasis 6

2. Don't stop methotrexate reflexively - it's actually recommended for RA-ILD management unless drug-induced pneumonitis is confirmed 5

3. Don't use mycophenolate mofetil - despite mention in other guidelines, it lacks evidence and doesn't improve joint manifestations 5

4. Don't ignore the increased mortality risk - patients with RA-associated bronchiectasis have poorer prognosis than either condition alone and require regular follow-up 3

5. Follow up within 4-6 weeks after initial evaluation to assess treatment response 1

Treatment Monitoring

Use validated cough severity tools to assess treatment outcomes 1. If cough remains refractory despite appropriate workup and treatment, consider referral to a specialized cough clinic 1.

The combination of RA with pulmonary manifestations requires coordinated care between rheumatology and pulmonology, as these patients face significantly increased morbidity and mortality 3, 7.